Highlights in Chronic Lymphocytic Leukemia From the 65th ASH Annual Meeting and Exposition

A Review of Selected Presentations From ASH 2023 December 9-12, 2023 • San Diego, California Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic […]

Genomic Risk Stratification in Chronic Lymphocytic Leukemia

H&O Which patients with chronic lymphocytic leukemia (CLL) require treatment? AW A substantial proportion of patients with CLL can go for decades with no need for […]

Preventing Infectious Complications in Chronic Lymphocytic Leukemia

H&O What causes the elevated risk of infections in patients with chronic lymphocytic leukemia (CLL)? CS Immunologic defects in patients with CLL are caused by the […]

Letter From the Editor: My Ongoing Debate

Some would argue that the first tenet of chronic lymphocytic leukemia (CLL) is to “watch and wait” until patients have an indication for treatment. This tenet […]

Managing CLL That Has Progressed After BTK Inhibition

H&O When patients with chronic lymphocytic leukemia (CLL) progress while on Bruton tyrosine kinase (BTK) inhibitor therapy, what is your next therapy of choice? LR Because […]

Highlights in Chronic Lymphocytic Leukemia from the 64th American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations from ASH 2022 December 10-13, 2022 • New Orleans, Louisiana Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results […]

The Use of Zanubrutinib in Chronic Lymphocytic Leukemia

H&O What makes the various Bruton tyrosine kinase (BTK) inhibitors different from one another? DB A variety of BTK inhibitors have been approved for use in […]

The Clinical Importance of Prognostic Markers in CLL

H&O How has the role of prognostic markers in chronic lymphocytic leukemia (CLL) changed with the transition from standard chemoimmunotherapy drugs to targeted agents? JA Since […]

Clinical Use of Measurable Residual Disease in CLL

H&O What are some of the limitations of the International Workshop on CLL (iwCLL) response criteria for chronic lymphocytic leukemia (CLL) in the era of novel […]

Highlights in Chronic Lymphocytic Leukemia From the 2022 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the ASCO Meeting • June 3-7, 2022 • Chicago, Illinois Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic […]

The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia

Abstract: Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods […]

Should Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL?

H&O Which patients with chronic lymphocytic leukemia (CLL) are eligible for treatment with venetoclax? RF Nearly all patients with CLL are eligible for treatment with venetoclax […]

Early Intervention in Asymptomatic Chronic Lymphocytic Leukemia

Abstract: Of the estimated 21,000 patients who will receive a new diagnosis of chronic lymphocytic leukemia (CLL) this year in the United States, approximately 80% will […]

Chimeric Antigen Receptor Natural Killer Cells for the Treatment of Patients With B-Cell Malignancies

H&O What are the outcomes associated with chimeric antigen receptor (CAR) T-cell therapy in patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)? KR […]

CLL In Focus

Complete Response Linked to Progression-Free Survival in Chronic Lymphocytic Leukemia Progression-free survival (PFS) is longer in patients with chronic lymphocytic leukemia (CLL) who have a complete […]

Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

H&O What type of drug is zanubrutinib? CT Zanubrutinib, also known as BGB-3111, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor. It inhibits BTK irreversibly […]

BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia

Abstract: Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) […]

Considerations in the Frontline Treatment of Chronic Lymphocytic Leukemia

H&O When is frontline therapy initiated in chronic lymphocytic leukemia (CLL)? SO The standard approach to CLL is still watch-and-wait. If patients are asymptomatic and […]

Highlights in Chronic Lymphocytic Leukemia From the 2016 American Society of Hematology Annual Meeting and Exposition

Special Reporting on:
• Five-Year Experience With Single-Agent Ibrutinib in Patients With Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
• Twice Daily Dosing With the Highly Specific BTK Inhibitor, BGB-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated With Durable Responses in Patients (pts) With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
• Integrated and Long-Term Safety Analysis of Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
• Acalabrutinib Monotherapy in Patients With Ibrutinib Intolerance: Results From the Phase 1/2 ACE-CL-001 Clinical Study
• Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib as First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
• Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination With Bendamustine and Rituximab in Patients With Relapsed/Refractory CLL
• CLL2-BIG – A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
PLUS Meeting Abstract Summaries
With Expert Commentary by:
Susan M. O’Brien, MD
Associate Director for Clinical Sciences, Chao Family Comprehensive Cancer Center
Medical Director, Sue and Ralph Stern Center for Clinical Trials & Research
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine
University of California, Irvine, Orange, California

The Evolving Role of Chemoimmunotherapy in Chronic Lymphocytic Leukemia

H&O What has been the traditional role of chemoimmunotherapy in patients with CLL? NL Traditionally, chemoimmunotherapy was the standard approach in both the frontline and […]